COMP <GO>
BYRN vs TMO // RETURN ON INVESTED CAPITAL (ROIC)
Byrna Technologies Inc. (NASDAQ) VS. Thermo Fisher Scientific Inc (NYSE) • 15-METRIC TALLY: BYRN 5
— TMO 7
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: BYRN
LAST: $4.30 (-9.66%) • MKT CAP: $111.4M
roic
18.00%
LAST: $697.00 (-1.72%) • MKT CAP: $262.22B
roic
9.30%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (BYRN VS. TMO)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | BYRN | TMO | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 60.50% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | 18.00% | 9.30% | +8.70 | BYRN | /roic <GO> |
| EV/EBITDA & P/E Valuation | 5.3x | 30.4x | -25.10 | BYRN | /valuation <GO> |
| Free Cash Flow Yield | -8.25% | 2.40% | -10.65 | TMO | /fcf-yield <GO> |
| Operating Margin | 10.00% | 17.40% | -7.40 | TMO | /operating-margins <GO> |
| Net Profit Margin | 8.20% | 15.10% | -6.90 | TMO | /net-margins <GO> |
| Revenue Growth (YoY) | 37.70% | 3.90% | +33.80 | BYRN | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.24% | -0.24 | TMO | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 5.31 | 4.50 | +0.81 | BYRN | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 8/9 | -4.00 | TMO | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 46.7 | 62.9 | -16.23 | TMO | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.94 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 9.7x | 36.3x | -26.60 | BYRN | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $111.4M | $262.22B | -$262.11B | TMO | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | BYRN REV | TMO REV | BYRN GROSS % | TMO GROSS % | BYRN FCF | TMO FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $118.1M | $44.56B | 60.5% | — | -$9.2M | $6.29B |
| FY 2024 | $85.8M | $42.88B | 61.5% | — | $9.4M | $7.27B |
| FY 2023 | $42.6M | $42.86B | — | — | $3.9M | $6.48B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
BYRN // BETA —
TMO // BETA 0.94